Lantern Pharma shareholders elect directors and approve stock option repricing
Lantern Pharma Shareholders Choose Directors and argue for reproduction of stock option
Lantern Pharma Shareholders Choose Directors and argue for reproduction of stock option
Trusted Editorial content, reviewed by leading industry experts and seasoned editors. Ad Disclosure Based on an SEC filing, Amplify — an asset manager overseeing $12.6 billion — has submitted paperwork for an XRP Option Income ETF that it plans to list on the Cboe BZX Exchange and start trading in November. Rather than buying XRP … Read more